Literature DB >> 10870805

Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment.

E de Raucourt1, G Meyer, P Landais, Z Gouaref, P Morinet, F Monge, H Sors, A M Fischer.   

Abstract

Plasma levels of prothrombin fragment 1+2 (Fl+2), thrombin-antithrombin complexes (TAT) and D-dimers were measured in 15 patients with pulmonary embolism during heparin therapy, oral anticoagulation, and after cessation of warfarin therapy. Each patient had a favorable outcome during anticoagulant therapy (3 months), but late venous thromboembolism occurred in six cases. The mean levels of the three markers were significantly increased on day 4 after the thrombotic event, and normalized during warfarin therapy. Nine months after the initial pulmonary embolism, mean levels of the three markers, as compared with a control population, were significantly higher in the patients with late recurrences, whereas only TAT were slightly higher in patients without recurrences as compared with controls. Only TAT levels were significantly higher in the patients with late recurrences than in those without late recurrences. Thus, the levels of the three markers 9 months after pulmonary embolism seem to be interesting to identify patients with high risk of recurrence and who might require longer anticoagulant treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870805

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  2 in total

1.  Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling.

Authors:  Emily Bontekoe; Yevgeniy Brailovsky; Debra Hoppensteadt; Jack Bontekoe; Fakiha Siddiqui; Joshua Newman; Omer Iqbal; Trent Reed; Jawed Fareed; Amir Darki
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

2.  Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).

Authors:  Jayne Tullett; Ellen Murray; Linda Nichols; Roger Holder; Will Lester; Peter Rose; F D Richard Hobbs; David Fitzmaurice
Journal:  BMC Cardiovasc Disord       Date:  2013-03-09       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.